Methods and compositions for treating cancer
AssigneeFlagship Pioneering Innovations V, Inc.
InventorsJordi MATA-FINK, Avak KAHVEJIAN, Jonathan Barry HUROV, Alexandra LANTERMANN
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for treating cancer using GRK2 inhibitors such as small molecule inhibitors of GRK2 among others. The invention also features compositions containing GRK2 inhibitors, methods of diagnosing patients with GRK2-associated cancer and methods of predicting the response of cancer in a subject to treatment with GRK2 inhibitors.
Claims85
A method of treating a subject with cancer, the method comprising administering to the subject an effective amount of a G-protein-coupled receptor kinase 2 (GRK2) small molecule antagonist.
A method of treating a subject with cancer, the method comprising contacting a tumor, tumor microenvironment, site of metastasis, cancer cell, metastatic cancer cell, or stromal cell in a tumor microenvironment with an effective amount of a GRK2 small molecule antagonist.
A method of treating a subject identified as having cancer, the method comprising administering to the subject an effective amount of a GRK2 small molecule antagonist.
A method of treating a subject identified as having cancer, the method comprising contacting a tumor, tumor microenvironment, site of metastasis, cancer cell, metastatic cancer cell, or stromal cell in a tumor microenvironment with an effective amount of a GRK2 small molecule antagonist.
A method of reducing or inhibiting cancer cell proliferation in a subject in need thereof, the method comprising administering to the subject an effective amount of a GRK2 small molecule antagonist.
A method of reducing or inhibiting cancer cell proliferation in a subject in need thereof, the method comprising contacting a cancer cell with an effective amount of a GRK2 small molecule antagonist.
A method of reducing or inhibiting cancer cell or tumor growth in a subject in need thereof, the method comprising administering to the subject an effective amount of a GRK2 small molecule antagonist.
A method of reducing or inhibiting cancer cell or tumor growth in a subject in need thereof, the method comprising contacting a tumor, tumor microenvironment, site of metastasis, cancer cell, metastatic cancer cell, or stromal cell in a tumor microenvironment with an effective amount of a GRK2 small molecule antagonist.
A method of treating a subject with cancer, the method comprising:
- (a) identifying a subject with GRK2-associated cancer;
- and (b) administering to the subject an effective amount of a GRK2 small molecule antagonist.
A method of treating a subject with cancer, the method comprising:
- (a) identifying a subject with GRK2-associated cancer;
- and (b) contacting a tumor, tumor microenvironment, site of metastasis, cancer cell, metastatic cancer cell, or stromal cell in a tumor microenvironment with an effective amount of a GRK2 small molecule antagonist.
A method of treating a subject with GRK2-associated cancer, the method comprising administering to the subject an effective amount of a GRK2 small molecule antagonist.
A method of treating a subject with GRK2-associated cancer, the method comprising contacting a tumor, tumor microenvironment, site of metastasis, cancer cell, metastatic cancer cell, or stromal cell in a tumor microenvironment with an effective amount of a GRK2 small molecule antagonist.
A method of predicting the response of a cancer in a subject to treatment with a GRK2 inhibitor, the method comprising contacting a cancer cell isolated from the subject with a GRK2 small molecule antagonist and evaluating the response of the cancer cell.
A method of predicting the response of a cancer in a subject to treatment with a GRK2 inhibitor, the method comprising:
- (a) isolating a cancer cell from the subject;
- (b) measuring the expression of GRK2 in the cancer cell;
- and (c) comparing GRK2 expression in the cancer cell to a reference, wherein increased expression of GRK2 in the cancer cell as compared to the reference indicates that the subject will respond to treatment with a small molecule antagonist.
An anti-cancer therapy comprising a GRK2 small molecule antagonist a second agent selected from the group consisting of chemotherapeutic agents, checkpoint inhibitors, biologic cancer agents, cancer-specific agents, cytokine therapies, anti-angiogenic drugs, drugs that target cancer metabolism, antibodies that mark a cancer cell surface for destruction, antibody-drug conjugates, cell therapies, commonly used anti-neoplastic agents, CAR-T therapies, oncolytic viruses, non-drug therapies, neurotransmission blockers, and neuronal growth factor blockers.
A pharmaceutical composition comprising a GRK2 small molecule antagonist and an anti-cancer therapeutic.
Dependencies are inferred from the claim text.